Key Points
- United Therapeutics EVP Paul Mahon sold 8,300 shares on April 16 at an average price of $576.82, totaling $4,787,606 and cutting his stake by 15.52% to 45,172 shares (≈$26.06M).
- In the latest quarter UTHR reported $7.70 EPS, topping the $6.78 consensus, while revenue came in at $790.2M versus estimates of $814.8M.
- Analysts remain positive with a consensus rating of "Moderate Buy" and a $601.50 target (several firms raised targets, including Raymond James to $700), and institutional investors own about 94.08% of the stock.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 75 shares of the firm's stock in a transaction on Friday, March 13th. The stock was sold at an average price of $536.95, for a total transaction of $40,271.25. Following the completion of the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $174,209,668.85. The trade was a 0.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.
United Therapeutics Trading Up 0.5%
Shares of UTHR stock opened at $580.51 on Friday. The firm has a market capitalization of $25.44 billion, a P/E ratio of 20.81, a price-to-earnings-growth ratio of 1.65 and a beta of 0.75. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $607.89. The firm's fifty day simple moving average is $524.67 and its 200 day simple moving average is $488.35.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same period last year, the business posted $6.19 EPS. The business's quarterly revenue was up 7.4% on a year-over-year basis. Equities research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.
Hedge Funds Weigh In On United Therapeutics
A number of hedge funds have recently modified their holdings of UTHR. Geneos Wealth Management Inc. boosted its stake in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after buying an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company's stock worth $127,000 after acquiring an additional 70 shares in the last quarter. Jump Financial LLC bought a new position in shares of United Therapeutics during the second quarter valued at $277,000. Cerity Partners LLC lifted its holdings in shares of United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company's stock valued at $3,691,000 after acquiring an additional 5,600 shares during the period. Finally, Bank of Nova Scotia grew its holdings in shares of United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company's stock worth $468,000 after purchasing an additional 105 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on UTHR. Morgan Stanley lifted their target price on United Therapeutics from $471.00 to $519.00 and gave the stock an "equal weight" rating in a research report on Friday, April 10th. Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, February 26th. Bank of America lifted their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a "neutral" rating in a report on Tuesday, March 31st. Jefferies Financial Group restated a "buy" rating on shares of United Therapeutics in a research report on Monday, March 2nd. Finally, Royal Bank Of Canada upped their target price on United Therapeutics from $587.00 to $643.00 and gave the company an "outperform" rating in a research note on Thursday, February 26th. Ten investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $601.50.
Check Out Our Latest Stock Analysis on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
